Search research articles
Contact Us
Filters
Showing results (41-50 of 85) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2008
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi, Stewart J Anderson, Harry D Bear, et al.
Pharmacogenetics and Genomics
|
May 17, 2018
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab
James N Ingle, Krishna R Kalari, Donald Lawrence Wickerham, et al.
Clinical Breast Cancer
|
October 4, 2016
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5
John W Smith, Marc E Buyse, Priya Rastogi, et al.
Breast Cancer Research and Treatment
|
March 22, 2023
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41
Priya Rastogi, Gong Tang, Saima Hassan, et al.
Cancer
|
April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer
PierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
JNCI Cancer Spectrum
|
September 6, 2021
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo
Pamela J Goodwin, Ryan J O Dowling, Marguerite Ennis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2024
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, et al.
Frontiers in Oncology
|
June 12, 2023
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
Pooja P Advani, Kathryn J Ruddy, Joerg Herrmann, et al.
The Lancet. Oncology
|
October 8, 2013
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
André Robidoux, Gong Tang, Priya Rastogi, et al.
JAMA Oncology
|
February 18, 2021
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
Otto Metzger Filho, Daniel G Stover, Sarah Asad, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 85) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2008
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi, Stewart J Anderson, Harry D Bear, et al.
Pharmacogenetics and Genomics
|
May 17, 2018
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab
James N Ingle, Krishna R Kalari, Donald Lawrence Wickerham, et al.
Clinical Breast Cancer
|
October 4, 2016
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5
John W Smith, Marc E Buyse, Priya Rastogi, et al.
Breast Cancer Research and Treatment
|
March 22, 2023
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41
Priya Rastogi, Gong Tang, Saima Hassan, et al.
Cancer
|
April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer
PierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
JNCI Cancer Spectrum
|
September 6, 2021
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo
Pamela J Goodwin, Ryan J O Dowling, Marguerite Ennis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2024
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, et al.
Frontiers in Oncology
|
June 12, 2023
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
Pooja P Advani, Kathryn J Ruddy, Joerg Herrmann, et al.
The Lancet. Oncology
|
October 8, 2013
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
André Robidoux, Gong Tang, Priya Rastogi, et al.
JAMA Oncology
|
February 18, 2021
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
Otto Metzger Filho, Daniel G Stover, Sarah Asad, et al.
Page
of 9